MAIA Biotechnology Announces Year-to-Date Highlights And Achievements, Including Clinical Progress Of Lead Candidate THIO, A First-In-Class Cancer Telomere Targeting Agent For Non-Small Cell Lung Cancer (NSCLC)
$MAIA
Biotechnology: Pharmaceutical Preparations
Health Care
- New science for cancer therapy drives powerful value proposition
- Exceptional measures of efficacy by lead drug THIO in Phase 2 clinical trial
- Funding of more than $12M year-to-date, including $7.4 million in Q2'24 so far
- Secured continued insider investment through independent board members' participation in private placement equity financings
- Newest data shows THIO's strong outperformance against standard-of-care treatments in non-small cell lung cancer (NSCLC)
- 38% overall response rate (ORR) in third-line (3L) setting (THIO 180mg) vs. ~6% for currently available treatments in a similar population
- 5.5 months median progression-free survival (PFS) (3L, THIO 180mg) more than double PFS of current chemotherapy treatments